Jonathan Brayman is a Managing Director in Blackstone Credit and Insurance (BXCI) based in New York and Cambridge. Mr. Brayman is focused on private credit, structured equity, and royalty monetizations in Healthcare & Life Sciences. Mr. Brayman has been involved in Blackstone’s investments in Alnylam Pharmaceuticals, Mannkind Corp, Axsome Therapeutics, XDEMVY Royalty, Amicus Therapeutics, PTC Therapeutics, Harmony Biosciences, Catalent, Simtra (fka Baxter Biopharma Solutions), Ritedose, Inovalon, Personify Health, among others.

Prior to joining Blackstone in 2015, Mr. Brayman worked as an Investment Banking Analyst at Houlihan Lokey, where he advised Healthcare companies on mergers and acquisitions.

Mr. Brayman graduated summa cum laude with a BS in Commerce and Business Administration and a double major in Finance and Economics from the University of Alabama. Mr. Brayman serves on the Board of Directors of Public Health Solutions.